Product Information

QUDEXY XR 200 MG CAPSULE is a brand product labeled by Upsher-Smith Laboratories LLC, priced at $32.8758 per EA under NDC 00245107330. Its NADAC has been published 175 times since Sep 18, 2019.

FDA first approved this application on Mar 11, 2014. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

QUDEXY XR 200 MG CAPSULE

Topiramate
$32.8758per EA

Strength

200 mg/1

NDC

00245107330

Classification

Brand

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Effective Date

4/23/2025

Active Ingredients

TOPIRAMATE

Approval Type

New Drug (NDA)

FDA Application

NDA205122

FDA Approved

3/11/2014

TE Code

AB2

On Market Since

4/11/2014

Pharmacological Classes

Cytochrome P450 2C19 Inhibitors
Cytochrome P450 3A4 Inducers
Decreased Central Nervous System Disorganized Electrical Activity

Price Statistics

The NADAC for QUDEXY XR 200 MG CAPSULE has been published 175 times since Sep 18, 2019, and over the history we have for it it has risen 22.3%. The table below summarizes its recorded NADAC range and movement.

Current price$32.8758 per EA
All-time high$32.8758 (Apr 15, 2026)
All-time low$26.8832 (Sep 18, 2019)
52-week high$32.8758
52-week low$32.8758
Median price$32.7310
Average price$30.9063
Largest weekly change+14.9% (Apr 17, 2024)
Weeks tracked175
Tracking sinceSep 18, 2019

Price History

1W

N/A

1M

N/A

3M

N/A

6M

0.0%

1Y

0.0%

3Y

+15.4%

5Y

+15.4%

All

+22.3%

Last surveyed Apr 15, 2026 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 71% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of QUDEXY XR 200 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for QUDEXY XR 200 MG CAPSULE, manufactured by Upsher-Smith Laboratories LLC, is $32.8758 per EA (NDC 00245107330), effective Apr 15, 2026.

How has the price of QUDEXY XR 200 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for QUDEXY XR 200 MG CAPSULE has risen 22.3%. It has been tracked across 175 weekly CMS publications since Sep 18, 2019.

What are the highest and lowest recorded NADAC prices for QUDEXY XR 200 MG CAPSULE?

Since Sep 18, 2019, the NADAC for QUDEXY XR 200 MG CAPSULE has ranged from a low of $26.8832 (Sep 18, 2019) to a high of $32.8758 (Apr 15, 2026), with a median of $32.7310 per EA.

Are there cheaper alternatives to QUDEXY XR 200 MG CAPSULE?

Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOPIRAMATE ER 200 MG SPRINK CAP, is $9.6713 per EA — about 71% below QUDEXY XR 200 MG CAPSULE.

Who manufactures QUDEXY XR 200 MG CAPSULE?

QUDEXY XR 200 MG CAPSULE (NDC 00245107330) is labeled by Upsher-Smith Laboratories LLC, and CMS classifies it as a brand product.